Small molecules vs. biologics: the “same” IP fight—different playbooks for generics and biosimilars
Most IP teams treat drug patents as if the strategy is transferable across modalities. It isn’t.
A small-molecule portfolio and a biologics portfolio ma…
Biopharma vendors don’t lose deals because they’re “too late.” They lose because they’re invisible—until it’s too late.
In EU markets, the tender cycle around loss of exclusivity (LoE) is brutal: once the patent clock runs out, procurement teams move f…
Pharma doesn’t always need a new molecule to make billions. It needs a new story.
For years, the industry’s “innovation” narrative has been anchored to breakthrough compounds—new targets, new mechanisms, new patents. But a quieter, more lucrative playb…
Biopharma is entering a new kind of “cliff”—not just patent expiration, but the operational scramble that follows it.
When loss of exclusivity hits, the market doesn’t simply get cheaper. It gets faster. Generics arrive with aggressive pricing, payers …
Most pharma teams don’t lose patent value because they miss deadlines—they lose it because they pick the wrong patent to extend.
That’s the uncomfortable truth behind “one-shot” patent strategy: when you’re trying to maximize drug patent term extension…
One Shot: How to Pick the Right Drug Patent for Maximum Drug Patent Term Extension Value Read Post »
Drug patent litigation isn’t just about what’s claimed—it’s about what’s designed around.
In the pharmaceutical world, “design around” sounds like a legal strategy. In practice, it’s an engineering discipline—one that starts with reading formulation …
Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …
Pharma has a $300 billion question it can’t afford to misread: Is it “patent term restoration” or “patent term adjustment”?
At first glance, the two sound like cousins—both extend exclusivity, both protect revenue, both buy time. But in practice, the…
Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…
Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
If you’re building a Eurasia strategy—whether for market entry, lifecycle management, or portfolio protection—this is the part that…
Drug Patents in Eurasia: What Every Pharma Executive Actually Needs to Know Read Post »
Get new actionable insights and updates from BiotechBlog
